Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients
NCT ID: NCT03880682
Last Updated: 2019-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2018-11-01
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HCV + to HCV - Kidney Transplant
NCT04320290
Hepatitis C Positive Donor Into Hepatitis C Negative Recipients
NCT03702218
Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
NCT03623568
Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients
NCT04605679
Immune Registry for BK in Kidney Transplant Recipients
NCT06538961
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Group
Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having a detectable level of HCV RNA.
* Having direct acting antivirals for 12 or 24 weeks.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Safak Mirioglu
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Safak Mirioglu, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Internal Medicine, Istanbul Faculty of Medicine
Halil Yazici, MD
Role: STUDY_CHAIR
Department of Internal Medicine, Istanbul Faculty of Medicine
Sabahattin Kaymakoglu, MD
Role: STUDY_CHAIR
Department of Internal Medicine, Istanbul Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul University
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C, Massetto B, Brainard DM, McHutchison JG, Bourliere M, Peck-Radosavljevic M, Manns M, Pol S. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. Ann Intern Med. 2017 Jan 17;166(2):109-117. doi: 10.7326/M16-1205. Epub 2016 Nov 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018/1511
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.